- Home
- LFUS vs RYTM Comparison
LFUS vs RYTM Comparison
Compare LFUS & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFUS
- RYTM
- Stock Information
- Founded
- LFUS 1927
- RYTM 2008
- Country
- LFUS United States
- RYTM United States
- Employees
- LFUS N/A
- RYTM N/A
- Industry
- LFUS Electrical Products
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- LFUS Energy
- RYTM Health Care
- Exchange
- LFUS Nasdaq
- RYTM Nasdaq
- Market Cap
- LFUS 6.7B
- RYTM 6.4B
- IPO Year
- LFUS N/A
- RYTM 2017
- Fundamental
- Price
- LFUS $241.77
- RYTM $100.21
- Analyst Decision
- LFUS Buy
- RYTM Strong Buy
- Analyst Count
- LFUS 3
- RYTM 12
- Target Price
- LFUS $292.50
- RYTM $116.25
- AVG Volume (30 Days)
- LFUS 191.7K
- RYTM 650.9K
- Earning Date
- LFUS 10-29-2025
- RYTM 11-04-2025
- Dividend Yield
- LFUS 1.24%
- RYTM N/A
- EPS Growth
- LFUS N/A
- RYTM N/A
- EPS
- LFUS 4.74
- RYTM N/A
- Revenue
- LFUS $2,321,865,000.00
- RYTM $174,334,000.00
- Revenue This Year
- LFUS $10.60
- RYTM $46.10
- Revenue Next Year
- LFUS $8.75
- RYTM $63.02
- P/E Ratio
- LFUS $50.85
- RYTM N/A
- Revenue Growth
- LFUS 5.78
- RYTM 54.92
- 52 Week Low
- LFUS $142.10
- RYTM $45.91
- 52 Week High
- LFUS $275.00
- RYTM $116.00
- Technical
- Relative Strength Index (RSI)
- LFUS 38.20
- RYTM 40.32
- Support Level
- LFUS $240.00
- RYTM $97.13
- Resistance Level
- LFUS $248.30
- RYTM $116.00
- Average True Range (ATR)
- LFUS 8.01
- RYTM 5.08
- MACD
- LFUS -2.46
- RYTM -1.76
- Stochastic Oscillator
- LFUS 15.81
- RYTM 24.77
About LFUS Littelfuse Inc.
Littelfuse is a primary provider of circuit protection products (such as fuses and relays) for the transportation, industrial, telecommunications, and consumer electronics end markets. The company is also increasing its power semiconductor business, where it predominantly serves industrial end markets, and is breaking into electric vehicle charging infrastructure. Littelfuse has 17,000 global employees.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.